Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. NASDAQ OMX GlobeNewswire Message Board

Orexo’s “Out the Monster” campaign wins a Go

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 301275
Posted On: 06/25/2015 2:15:09 AM
Avatar
Posted By: News Desk 2018
Orexo’s “Out the Monster” campaign wins a Gold Lions Health Award at the Cannes Lions Festival

Morristown, NJ - June 25, 2015 - Orexo’s “Out the Monster” campaign came out on top with a Gold Lions Health Award at the Cannes Lions Festival in France on June 19th. The Lions Health Awards recognize the most creative ideas in the healthcare and pharmaceutical communications industry. “Out the Monster” is a disease awareness campaign featuring a provocative image of a “monster” to depict accidental opioid addiction. Then telling the story of patients who became dependent through legitimate opioid use that originally began with a prescription from a health care provider. “Out the Monster” aims to empower and encourage patients to come forward and face the “monster” so they may seek the treatment they both need and deserve. Every year, thousands of people who are prescribed painkillers become accidentally addicted, and because of the stigma associated with this addiction, many patients are reluctant to seek help. The “Out the Monster” campaign is arming health care providers with thousands of fully illustrated books and a short video telling the story of the “monster,” and equipping patients with critical information on the campaign’s web site, www.outthemonster.com, to encourage them to feel confident to seek treatment. “We are honored to receive recognition at the Cannes Lions Festival for the ‘Out the Monster’ campaign,” said Robert DeLuca, R.Ph., President, Orexo US, Inc. “We developed this campaign to fill a huge chasm in this therapeutic area with regard to understanding that accidental opioid addiction is a disease which unfortunately is of epidemic proportion in the United States. We are proud to further differentiate Orexo’s commitment by starting this movement that encourages people to rally together and do more to address the epidemic of accidental opioid addiction. This critically important issue has been hidden or ignored for far too long, and we are proud to ignite a debate and encourage progress.” “The feedback we have received on the campaign has been overwhelmingly positive. It is a testimony that our organization in the US has reached into the core of the problem of opioid addiction enabling improved dialog with all stakeholders every day in the US on how stop the monster accidental opioid addiction,” said Nikolaj Sorensen, CEO and President, Orexo AB. About “Out the Monster” The “Out the Monster” campaign was developed to further educate the public and generate the empathy necessary to de-stigmatize the disease of accidental opioid addiction. All campaign assets aim to drive the public to www.outthemonster.com to learn more about accidental opioid addiction. The “Out the Monster” campaign features a short film, digital and social elements and media, events and leadership conferences, as well as a book. Orexo created the campaign in partnership with StrawberryFrog, a New York-based advertising agency. For further information, please contact: Robert DeLuca, President, Orexo US, Inc. Tel: +1 973 936 6990, E-mail: info-us@orexo.com Nikolaj Sørensen, President and CEO, Orexo AB Tel: +46 (0)703-50 78 88, E-mail: ir@orexo.com About Orexo US, Inc. Orexo US, Inc. is an emerging specialty pharmaceutical company marketing improved treatments for opioid dependence using proprietary drug delivery technology. To receive more information please contact Orexo at 1-855-ZUBSOLV. www.orexo-us.com (http://httP//www.orexo-us.com) About Orexo AB Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for maintenance treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo’s share is listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in Uppsala, Sweden. www.orexo.com



(0)
(0)








Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us